AU782094B2 - Bioavailable dosage form of isotretinoin - Google Patents

Bioavailable dosage form of isotretinoin Download PDF

Info

Publication number
AU782094B2
AU782094B2 AU44459/01A AU4445901A AU782094B2 AU 782094 B2 AU782094 B2 AU 782094B2 AU 44459/01 A AU44459/01 A AU 44459/01A AU 4445901 A AU4445901 A AU 4445901A AU 782094 B2 AU782094 B2 AU 782094B2
Authority
AU
Australia
Prior art keywords
formulation
less
oil
acid
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44459/01A
Other languages
English (en)
Other versions
AU4445901A (en
Inventor
Inderdeep Bhatia
Rajiv Malik
Abha Pant
Sunilendu Bhushan Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of AU4445901A publication Critical patent/AU4445901A/en
Application granted granted Critical
Publication of AU782094B2 publication Critical patent/AU782094B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU44459/01A 2000-06-16 2001-04-09 Bioavailable dosage form of isotretinoin Ceased AU782094B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN596/DEL/00 2000-06-16
IN596DE2000 IN192188B (enExample) 2000-06-16 2000-06-16
PCT/IB2001/000581 WO2001095886A1 (en) 2000-06-16 2001-04-09 Bioavailable dosage form of isotretinoin

Publications (2)

Publication Number Publication Date
AU4445901A AU4445901A (en) 2001-12-24
AU782094B2 true AU782094B2 (en) 2005-06-30

Family

ID=11097063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44459/01A Ceased AU782094B2 (en) 2000-06-16 2001-04-09 Bioavailable dosage form of isotretinoin

Country Status (25)

Country Link
US (1) US6740337B2 (enExample)
EP (1) EP1294357A1 (enExample)
JP (1) JP2004503493A (enExample)
CN (1) CN1196475C (enExample)
AP (1) AP2002002423A0 (enExample)
AU (1) AU782094B2 (enExample)
BG (1) BG106414A (enExample)
BR (1) BR0106752A (enExample)
CA (1) CA2382065A1 (enExample)
CZ (1) CZ2002694A3 (enExample)
EA (1) EA004808B1 (enExample)
EE (1) EE200200074A (enExample)
HK (1) HK1052302A1 (enExample)
HR (1) HRP20020148A2 (enExample)
HU (1) HUP0203717A3 (enExample)
IL (1) IL148176A0 (enExample)
IN (1) IN192188B (enExample)
MX (1) MXPA02001669A (enExample)
NZ (1) NZ517142A (enExample)
OA (1) OA12008A (enExample)
PL (1) PL352838A1 (enExample)
SK (1) SK2252002A3 (enExample)
UA (1) UA74793C2 (enExample)
WO (1) WO2001095886A1 (enExample)
ZA (1) ZA200201240B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2225600T3 (es) * 2000-09-22 2005-03-16 Galephar M/F Composicion semi-solida de isotretinoina.
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
US20070099996A1 (en) * 2003-05-20 2007-05-03 Shashikanth Isloor Pharmaceutical compositions of acitretin
US20070254858A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
US20070254025A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
RU2322998C1 (ru) * 2006-11-16 2008-04-27 Общество с ограниченной ответственностью "Березовый мир" Носитель лекарственных и диагностических средств
KR101434706B1 (ko) * 2007-02-16 2014-08-26 아스카 세이야쿠 가부시키가이샤 미립자 유성 현탁액을 포함하는 의약 조성물
WO2008102375A2 (en) * 2007-02-20 2008-08-28 Ipca Laboratories Limited A process for preparation of highly pure isotretinoin
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
CA2987177A1 (en) * 2015-05-25 2016-12-01 Sun Pharmaceutical Industries Limited Once-daily oral pharmaceutical composition of isotretinoin
US10517846B2 (en) 2016-05-26 2019-12-31 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for treating acne
KR20250054055A (ko) * 2022-07-01 2025-04-22 아크로테크 바이오파마 인코포레이티드. 이소트레티노인을 포함하는 제약 조성물 및 그의 제조 방법 및 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184942A2 (en) * 1984-12-14 1986-06-18 Ortho Pharmaceutical Corporation Improved pharmaceutical composition containing 13-CIS vitamin a acid as the active ingredient
WO2000025772A1 (en) * 1998-10-30 2000-05-11 F. Hoffmann-La Roche Ag Compositions of and process for producing isotretinoin having low particle size

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
US4808630A (en) 1987-01-16 1989-02-28 United States Of America Method of treating psychotic illnesses
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6284283B1 (en) * 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184942A2 (en) * 1984-12-14 1986-06-18 Ortho Pharmaceutical Corporation Improved pharmaceutical composition containing 13-CIS vitamin a acid as the active ingredient
WO2000025772A1 (en) * 1998-10-30 2000-05-11 F. Hoffmann-La Roche Ag Compositions of and process for producing isotretinoin having low particle size

Also Published As

Publication number Publication date
EA004808B1 (ru) 2004-08-26
HRP20020148A2 (en) 2003-12-31
SK2252002A3 (en) 2002-08-06
HK1052302A1 (zh) 2003-09-11
WO2001095886A1 (en) 2001-12-20
EE200200074A (et) 2003-04-15
US20020025338A1 (en) 2002-02-28
ZA200201240B (en) 2002-09-02
IL148176A0 (en) 2002-09-12
UA74793C2 (en) 2006-02-15
BR0106752A (pt) 2002-04-16
MXPA02001669A (es) 2002-08-06
CN1196475C (zh) 2005-04-13
CN1388757A (zh) 2003-01-01
OA12008A (en) 2006-04-19
AU4445901A (en) 2001-12-24
CZ2002694A3 (cs) 2002-08-14
AP2002002423A0 (en) 2002-03-31
EA200200166A1 (ru) 2002-10-31
US6740337B2 (en) 2004-05-25
HUP0203717A3 (en) 2003-05-28
HUP0203717A2 (hu) 2003-04-28
IN192188B (enExample) 2004-03-13
PL352838A1 (en) 2003-09-08
CA2382065A1 (en) 2001-12-20
JP2004503493A (ja) 2004-02-05
NZ517142A (en) 2003-08-29
EP1294357A1 (en) 2003-03-26
BG106414A (en) 2002-09-30

Similar Documents

Publication Publication Date Title
EP0184942B1 (en) Improved pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
US7422758B2 (en) Sustained release vitamin composition
AU613663B2 (en) Sustained release etodolac
US7314643B2 (en) Soft capsule preparation
CA2690488C (en) Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
JPH07116021B2 (ja) 医薬品のカプセル化の簡易化
US6740337B2 (en) Bioavailable dosage form of isotretinoin
US20030232097A1 (en) Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
AU748396B2 (en) Composition
US5922351A (en) Lubricants for use in tabletting
JPS6230965B2 (enExample)
CN120694962A (zh) 硬胶囊剂型和其用途
US20050129773A1 (en) Isotretinoin nanoparticulate compositions
CN116350598A (zh) 一种用于维生素d类药物的成膜组合物及其药物制剂和制备方法
CZ287149B6 (en) Pharmaceutical preparation containing gemfibrozil
IE62426B1 (en) Pharmaceutical composition for 4-aroylimidazol-2-ones
CN118304270A (zh) 一种维生素d滴剂及其制备方法
CN118304279A (zh) 一种骨化三醇自微乳口溶膜及其制备方法
WO2002060437A1 (en) Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
AU2002240206A1 (en) Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
BG62234B1 (bg) Фармацевтични състави,съдържащи гемфиброзил